1 October 2024

Howe Street Reporter Title

Category: Biotech

  • Filament Health (FN.NEO) – Five Easy Questions with Maddy

    Filament Health (FN.NEO) – Five Easy Questions with Maddy

    Welcome to Five Easy Questions with Maddy Grace where we explain the public markets and the companies that trade on them. In today’s episode, Maddy speaks with Ben Lightburn, CEO of Filament Health, a new psychedelics company with a patented process for extracting compounds naturally and bottling them in consistent dose levels. Enjoy!

  • BetterLife Pharma (BETR.C) products show promise, but how’s their timing?

    BetterLife Pharma (BETR.C) products show promise, but how’s their timing?

    Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you after proving that it has these benefits during the regulatory dance, you take it to a new market, rebrand it and resell it. Easy. Or you…

  • Analysis: BetterLife (BETR.C) implements a business-minded and cost-conscious approach to product research and development

    Analysis: BetterLife (BETR.C) implements a business-minded and cost-conscious approach to product research and development

    BetterLife is a biotechnology company that develops and commercializes psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. Products Although the table below may seem complex is just a collection of the product names or titles and a description with the type of disease the product…

  • Analysis :Bionano Genomics (BNGO.Q) life sciences

    Analysis :Bionano Genomics (BNGO.Q) life sciences

    Bionano Genomics operates as a life sciences instrumentation company in the genome analysis space that provides tools and services based on their Saphyr system to scientists and clinicians conducting genetic research and patient testing and provides diagnostic testing for those with autism spectrum disorder and other neurodevelopmental disabilities through Lineagen, their wholly owned subsidiary. I…

  • To Invest or Not: Diagnos (ADK.V)

    To Invest or Not: Diagnos (ADK.V)

    In this episode, we talk about DIAGNOS (ADK.V), a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment. We discuss what they do,…

  • Chris’ Corner: Diagnos Inc (ADK.V)

    Chris’ Corner: Diagnos Inc (ADK.V)

    Chris Parry speaks with Andre Larente, president and CEO of DIAGNOS (ADK.V) to get an in-depth look at how their diabetic retinopathy screening services work and what it means for optometrists and patients. Tune in!

  • Psychedelic Weekly Roundup with MNMD.Q, MSET.C, MYND.C, MEDI.NE, AWKN.NE, SILO, MCUR.C, NOVA.C, TRYP.C, TPIA, NEON.C

    Psychedelic Weekly Roundup with MNMD.Q, MSET.C, MYND.C, MEDI.NE, AWKN.NE, SILO, MCUR.C, NOVA.C, TRYP.C, TPIA, NEON.C

    Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine (MNMD.Q, MMED.NE) MindMed announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate to…

  • Bioasis Technologies (BTI.V): To Invest or Not?

    Bioasis Technologies (BTI.V): To Invest or Not?

    For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary…

  • Bioasis (BTI.V) revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain

    Bioasis (BTI.V) revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain

    Bioasis is a preclinical biopharmaceutical company focused on research and early-stage development of technologies and products for the treatment of patients with the central nervous system, or CNS, diseases, and disorders. In layman’s terms, this is a company that researches and develops products for the diagnosis and treatment of neurological diseases and disorders. The company…

  • Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)

    Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)

    Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical…